Laboratorios Farmaceuticos ROVI (ROVI)

Real-time derived


	Symbol		Exchange		Currency
	ROVI		Madrid		EUR	Delayed
	ROVI		Derived		EUR	Real-time
	ROVI		Vienna		EUR	Real-time

Currency in EUR

Disclaimer

72.500

-0.950(-1.29%)

Closed02:35:59

Fair Value

Day's Range

72.200

73.550

52 wk Range

46.780

94.800

ROVI Income Statement

Featured here, the Income Statement (earnings report) for Laboratorios Farmaceuticos ROVI, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).

Advanced Income Statement

Period Ending:

2014

31/12

2015

31/12

2016

31/12

2017

31/12

2018

31/12

2019

31/12

2020

31/12

2021

31/12

2022

31/12

2023

31/12

Total Revenues

381.31

419.96

648.68

817.7

829.51

Total Revenues Growth

+25.76%

+10.14%

+54.46%

+26.06%

+1.44%

Cost Of Revenues

169.88

182.83

268.84

305.27

346.17

Gross Profit

211.43

237.14

379.84

512.43

483.34

Gross Profit Growth

+23.6%

+12.16%

+60.18%

+34.91%

-5.68%

Gross Profit Margin %

55.45%

56.47%

58.56%

62.67%

58.27%

Other Operating Expenses, Total

169.4

162.22

199.68

258.69

263.87

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	+9.16%	-4.24%	+23.1%	+29.55%	+2%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	-	-
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	92.22	84.83	103.36	129.99	147.02
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	58.96	57.8	74.96	105.84	92.52

Operating Income

42.03

74.92

180.15

253.74

219.47

Operating Income Growth

+164.84%

+78.24%

+140.46%

+40.85%

-13.5%

EBIT Margin %

11.02%

17.84%

27.77%

31.03%

26.46%

Net Interest Expenses

-0.6

-1.07

-0.84

-0.84

-0.94

Net Interest Expenses Growth

+14.22%

-78.89%

+21.63%

-0.72%

-11.63%

Interest Expense, Total

-0.65

-1.07

-0.91

-0.85

-0.95

Interest And Investment Income

0.05

0

0.07

0.01

0.01

Other Non Operating Expenses, Total

0.79

0.12

3.41

3.31

1.88

EBT, Excl. Unusual Items

42.22

73.98

182.72

256.21

220.41

Gain (Loss) On Sale Of Assets

-

-

-

-

-

Other Unusual Items, Total

-0.34

-1.39

-0.1

-0

-

EBT, Incl. Unusual Items

41.88

72.58

182.63

257.97

220.41

EBT, Incl. Unusual Items Growth

+151.08%

+73.31%

+151.62%

+41.25%

-14.56%

EBT, Incl. Unusual Items Margin

10.98%

17.28%

28.15%

31.55%

26.57%

Income Tax Expense

2.61

11.52

29.55

58.3

50.11

Net Income to Company

39.27

61.06

153.08

199.67

170.3

Minority Interest

-

-

-

0

0.04

Net Income

39.27

61.06

153.08

199.67

170.34

Net Income Growth

+119.46%

+55.47%

+150.71%

+30.44%

-14.69%

Net Income Margin %

10.3%

14.54%

23.6%

24.42%

20.53%

Preferred Dividend and Other Adjustments

-

-

-

-

-

Net Income to Common Excl. Extra Items

39.27

61.06

153.08

199.67

170.34

Basic EPS - Continuing Operations

0.71

1.1

2.76

3.73

3.2

Basic EPS - Continuing Operations Growth

+103.73%

+54.89%

+150.63%

+35.16%

-14.25%

Diluted EPS - Continuing Operations

0.71

1.1

2.76

3.73

3.2

Diluted EPS - Continuing Operations Growth

+103.73%

+54.89%

+150.37%

+35.31%

-14.25%

Basic Weighted Average Shares Outstanding

55.18

55.39

55.4

53.47

53.19

Diluted Weighted Average Shares Outstanding

55.18

55.39

55.4

53.47

53.19

Dividend Per Share

0.18

0.38

0.96

1.29

1.1

Dividend Per Share Growth

+119.42%

+117.7%

+150.68%

+35.39%

-14.69%

EBITDA

55.44

89.61

196.56

271.33

238.02

EBITDA Growth

+105.45%

+61.62%

+119.36%

+38.04%

-12.28%

EBITDA Margin %

14.54%

21.34%

30.3%

33.18%

28.69%

EBIT